Objective: This paper aims to discuss the clinical effects of selenium yeast and levothyroxine combined therapy on patients with lymphocytic thyroiditis.
Methods: Eighty patients with lymphocytic thyroiditis, who were admitted in our hospital from July 2015 to June 2017, were enrolled and randomly and equally divided into control and experimental groups. The control group was treated with levothyroxine, whereas the experimental group was treated with selenium yeast and levothyroxine combined therapy. The clinical effects and relevant indexes of the two groups were statistically analysed.
Results: The experimental group presented a total therapeutic effect of 90.0%, which was considerably higher than that of the control group (70.0%), and the difference was statistically significant (P<0.05). The thyroid stimulating hormone, thyroid peroxidase antibody, and thyroglobulin antibodies of the experimental group were significantly lower than those of the control group (P<0.05). The peripheral blood T-lymphocyte subpopulation indexes (i.e., CD4/CD3, CD4/CD8, and CD8/CD3) of the experimental group were significantly higher than those of the control group (P<0.05). The recovery time and total treatment time of the experimental group were substantially shorter than those of the control group (P<0.05).
Conclusions: Selenium yeast and levothyroxine combined therapy demonstrated outstanding clinical effects on patients with lymphocytic thyroiditis, effectively improving the thyroid function and accelerating the recovery of the patients. Therefore, this combined therapy strategy has promising potential for clinical application.Author(s): Di Wu, Li Jin, Hongshuang Xu